SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
________________
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D) OF
THE SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported) May 25, 1995
SCIOS NOVA INC.
(Exact Name of Registrant as Specified in Charter)
Delaware 0-11749 95-3701481
(State of Other Jurisdiction (Commission (IRS Employer
of Incorporation) File Number) Identification No.)
2450 Bayshore Parkway, Mountain View, California 94043
(Address of Principal Executive Offices)
Registrant's telephone number, including area code 415-966-1550
<PAGE>
Item 5. Other Events
On May 25, 1995, Scios Nova Inc. was served with three complaints filed
in the United States District Court for the Northern District of California
by three shareholders. The actions were filed against the Company and
Richard Casey, its Chairman and Chief Executive Officer. The plaintiffs, who
seek to represent a class of persons who purchased common stock of the
Company between October 6, 1993 and May 2, 1995, assert claims against the
defendants for violations of Sections 10(b) and 20(a) of the Securities and
Exchange Act of 1934 in connection with Company statements regarding one of
its products, AURICULIN -Registered Trademark- anaritide.
The Company believes that it has meritorious defenses to the claims
and intends to mount a vigorous defense.
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this amendment to be signed on its behalf of the
undersigned, thereunto duly authorized.
SCIOS NOVA INC.
Date: June 8, 1995 By: /s/ John H. Newman
John H. Newman
Vice President of Legal Affairs
